Novartis
NEWS
In the lead-up to the ASCO Annual Meeting, companies were presenting some of their trial data, while other companies were presenting news related to COVID-19 studies. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 28, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 11, 2020.
Dyno says that with its research-and-development and collaboration deals with biopharma companies, it is potentially eligible for more than $2 billion in upfront payments, research support, and various milestones and option fees.
Developed by Novartis, the drug, Tabrecta, is designed for a type of NSCLC that has spread to other parts of the body and cannot be removed by surgery.
Many of the companies reported increased sales for the quarter as customers increased stockpiles and inventory in preparation for the pandemic, while other forms of sales and clinical trials were negatively impacted.
Despite the domination of the news cycle by the COVID-19 pandemic, quite a number of biopharma companies reported on non-COVID-19 clinical trials last week, although there remains plenty of ongoing trial news related to the pandemic. Here’s a look.
The COVID-19 pandemic is having a devastating effect on global business and biopharma companies are not excluded.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 20, 2020.
JOBS
IN THE PRESS